Tags

Type your tag names separated by a space and hit enter

Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling.
Int J Oncol. 2006 Sep; 29(3):695-703.IJ

Abstract

Ganoderma lucidum, an oriental medical mushroom, has been used in Asia for the prevention and treatment of a variety of diseases, including cancer. We have previously demonstrated that G. lucidum inhibits growth and induces cell cycle arrest at G0/G1 phase through the inhibition of Akt/NF-kappaB signaling in estrogen-independent human breast cancer cells. However, the molecular mechanism(s) responsible for the inhibitory effects of G. lucidum on the proliferation of estrogen-dependent (MCF-7) and estrogen-independent (MDA-MB-231) breast cancer cells remain to be elucidated. Here, we show that G. lucidum inhibited the proliferation of breast cancer MCF-7 and MDA-MB-231 cells by the modulation of the estrogen receptor (ER) and NF-kappaB signaling. Thus, G. lucidum down-regulated the expression of ERalpha in MCF-7 cells but did not effect the expression of ERbeta in MCF-7 and MDA-MB-231 cells. In addition, G. lucidum inhibited estrogen-dependent as well as constitutive transactivation activity of ER through estrogen response element (ERE) in a reporter gene assay. G. lucidum decreased TNF-alpha-induced (MCF-7) as well as constitutive (MDA-MB-231) activity of NF-kappaB. The inhibition of ER and NF-kappaB pathways resulted in the down-regulation of expression of c-myc, finally suppressing proliferation of estrogen-dependent as well as estrogen-independent cancer cells. Collectively, these results suggest that G. lucidum inhibits proliferation of human breast cancer cells and contain biologically active compounds with specificity against estrogen receptor and NF-kappaB signaling, and implicate G. lucidum as a suitable herb for chemoprevention and chemotherapy of breast cancer.

Authors+Show Affiliations

Cancer Research Laboratory, Methodist Research Institute, Indianapolis, IN 46202, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16865287

Citation

Jiang, Jiahua, et al. "Ganoderma Lucidum Inhibits Proliferation of Human Breast Cancer Cells By Down-regulation of Estrogen Receptor and NF-kappaB Signaling." International Journal of Oncology, vol. 29, no. 3, 2006, pp. 695-703.
Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol. 2006;29(3):695-703.
Jiang, J., Slivova, V., & Sliva, D. (2006). Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. International Journal of Oncology, 29(3), 695-703.
Jiang J, Slivova V, Sliva D. Ganoderma Lucidum Inhibits Proliferation of Human Breast Cancer Cells By Down-regulation of Estrogen Receptor and NF-kappaB Signaling. Int J Oncol. 2006;29(3):695-703. PubMed PMID: 16865287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. AU - Jiang,Jiahua, AU - Slivova,Veronika, AU - Sliva,Daniel, PY - 2006/7/26/pubmed PY - 2006/10/6/medline PY - 2006/7/26/entrez SP - 695 EP - 703 JF - International journal of oncology JO - Int J Oncol VL - 29 IS - 3 N2 - Ganoderma lucidum, an oriental medical mushroom, has been used in Asia for the prevention and treatment of a variety of diseases, including cancer. We have previously demonstrated that G. lucidum inhibits growth and induces cell cycle arrest at G0/G1 phase through the inhibition of Akt/NF-kappaB signaling in estrogen-independent human breast cancer cells. However, the molecular mechanism(s) responsible for the inhibitory effects of G. lucidum on the proliferation of estrogen-dependent (MCF-7) and estrogen-independent (MDA-MB-231) breast cancer cells remain to be elucidated. Here, we show that G. lucidum inhibited the proliferation of breast cancer MCF-7 and MDA-MB-231 cells by the modulation of the estrogen receptor (ER) and NF-kappaB signaling. Thus, G. lucidum down-regulated the expression of ERalpha in MCF-7 cells but did not effect the expression of ERbeta in MCF-7 and MDA-MB-231 cells. In addition, G. lucidum inhibited estrogen-dependent as well as constitutive transactivation activity of ER through estrogen response element (ERE) in a reporter gene assay. G. lucidum decreased TNF-alpha-induced (MCF-7) as well as constitutive (MDA-MB-231) activity of NF-kappaB. The inhibition of ER and NF-kappaB pathways resulted in the down-regulation of expression of c-myc, finally suppressing proliferation of estrogen-dependent as well as estrogen-independent cancer cells. Collectively, these results suggest that G. lucidum inhibits proliferation of human breast cancer cells and contain biologically active compounds with specificity against estrogen receptor and NF-kappaB signaling, and implicate G. lucidum as a suitable herb for chemoprevention and chemotherapy of breast cancer. SN - 1019-6439 UR - https://www.unboundmedicine.com/medline/citation/16865287/Ganoderma_lucidum_inhibits_proliferation_of_human_breast_cancer_cells_by_down_regulation_of_estrogen_receptor_and_NF_kappaB_signaling_ L2 - http://www.spandidos-publications.com/ijo/29/3/695 DB - PRIME DP - Unbound Medicine ER -